|
1）Ziamajidi N, Khaghani S, Hassanzadeh G, et al. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. Food Chem Toxicol. 2013; 58(8): 198-209
|
|
|
|
2）Wu J, Wang C, Li S, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis.Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by Liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice. Hepatology. 2013; 58(2): 617-28
|
|
|
|
|
3）Maliken BD, Nelson JE, Klintworth HM, et al. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology. 2013; 57(5): 1806-13
|
|
|
|
|
|
4）Chen QR, Braun R, Hu Y, et al. Multi-SNP analysis of GWAS data identifies pathways associated with nonalcoholic fatty liver disease. PLoS One. 2013; 8(7): e65982
|
|
|
|
|
|
5） Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011; 26 Suppl 1: 163-72
|
|
|
|
|
|
6）Moylan CA, Pang H, Dellinger A, et al. Hepatic gene expression profiles differentiate pre-symptomatic patients with mild versus severe nonalcoholic fatty liver disease (Severe NAFLD Gene Signature). Hepatology. 2013. In print
|
|
|
|
|
|
7）Ishikawa S, Ikejima K, Yamagata H, et al. CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. J Hepatol. 2011; 54(6): 1195-204
|
|
|
|
|
|
8）Yamagata H, Ikejima K, Takeda K, et al. Altered expression and function of hepatic natural killer T cells in obese and diabetic KK-A(y) mice. Hepatol Res. 2013; 43(3): 276-88
|
|
|
|
|
9）Satoh D, Yagi T, Nagasaka T, et al. CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. World J Hepatol. 2013; 5(4): 189-95
|
|
|
|
|
|
10）Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012; 142(7): 1592-609
|
|
|
|
|
|
11）Chen J, Zhu Y, Zheng Q, et al. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2013; Jul 9. [in print]
|
|
|
|
|
|
12）Kamada Y, Fujii H, Fujii H, et al. Serum Mac-2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics Clin Appl. 2013. In print
|
|
|
|
|
|
13）Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013; S0016-5085(13): 01012-3
|
|
|
|
|
|
14）Eckard C, Cole R, Lockwood J, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial.Therap Adv Gastroenterol. 2013; 6(4): 249-59
|
|
|
|
|
|
15）Bell LN, Wang J, Muralidharan S, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012; 56(4): 1311-8
|
|
|
|
|
|
16）Samson SL, Bajaj M. Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications. 2013; 27(4): 401-6
|
|
|
|
|
|
17）Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg. 2012; 75(2): 240-4
|
|
|
|
|
|
18）Staels B, Rubenstrunk A, Noel B, et al. Hepato-protective effects of the dual PPARα/δ agonist GFT505 in rodent models of NAFLD/NASH. Hepatology. 2013; 58: 1941-52
|
|
|
|
|
|
19）Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects. Diabetes Care. 2013; 36(10): 2923-30
|
|
|
|
|
|
20）Bechmann LP, Kocabayoglu P, Sowa JP, et al. .Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology. 2013; 57(4): 1394-406
|
|
|
|
|
|
21）Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid x receptor agonist obeticholic Acid in patients with type 2 diabetes and nonalcoholic Fatty liver disease. Gastroenterology. 2013; 145(3): 574-82
|
|
|
|
|